114 related articles for article (PubMed ID: 22629121)
21. Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.
Stewart DA; Bahlis N; Valentine K; Balogh A; Savoie L; Morris DG; Jones A; Brown C; Russell JA
Blood; 2006 Jun; 107(12):4623-7. PubMed ID: 16467197
[TBL] [Abstract][Full Text] [Related]
22. The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin's lymphoma.
Zeng J; Yang L; Huang F; Hong T; He Z; Lei J; Sun H; Lu Y; Hao X
Cancer Chemother Pharmacol; 2016 Oct; 78(4):801-8. PubMed ID: 27562137
[TBL] [Abstract][Full Text] [Related]
23. [Predictive significance of serum 90K/Mac-2BP on chemotherapy response in non-Hodgkin's lymphoma].
Zhang DS; Jiang WQ; Li S; Zhang XS; Mao H; Chen XQ; Li YH; Zhan J; Wang FH
Ai Zheng; 2003 Aug; 22(8):870-3. PubMed ID: 12917038
[TBL] [Abstract][Full Text] [Related]
24. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of cyclophosphamide,epirubicin, vincristine, prednisone, and etoposide (CEOP-E) for aggressive non-Hodgkin 's lymphoma.
Kim JG; Sohn SK; Kim DH; Baek JH; Park TI; Lee KB
J Korean Med Sci; 2004 Dec; 19(6):820-5. PubMed ID: 15608392
[TBL] [Abstract][Full Text] [Related]
26. [Primary study of relationship between serum level of VEGF and non-Hodgkin's lymphoma in children and adolescent patients].
Xia Y; Sun XF; Zhang CQ; Zhen ZJ; Wang ZH; Wang ZQ
Ai Zheng; 2004 Nov; 23(11 Suppl):1448-50. PubMed ID: 15566654
[TBL] [Abstract][Full Text] [Related]
27. Cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and radiotherapy for stage I intermediate or high grade non-Hodgkin's lymphomas: results of a strategy that adapts radiotherapy dose to the response after chemotherapy.
Krol AD; Berenschot HW; Doekharan D; Henzen-Logmans S; van der Holt B; van 't Veer MB
Radiother Oncol; 2001 Mar; 58(3):251-5. PubMed ID: 11230885
[TBL] [Abstract][Full Text] [Related]
28. Treatment of diffuse histiocytic and diffuse mixed non-Hodgkin lymphomas with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP).
Cohen Y; Epelbaum R; Ben-Shahar M; Ron Y; Haim N
Acta Oncol; 1988; 27(5):531-5. PubMed ID: 3203011
[TBL] [Abstract][Full Text] [Related]
29. Treatment results of chemoradiation therapy for localized aggressive lymphomas: A retrospective 20-year study.
Yamashita H; Izutsu K; Nakamura N; Shiraishi K; Chiba S; Kurokawa M; Tago M; Igaki H; Ohtomo K; Nakagawa K
Ann Hematol; 2006 Aug; 85(8):523-9. PubMed ID: 16691398
[TBL] [Abstract][Full Text] [Related]
30. Long term outcome of localized aggressive non-Hodgkin lymphoma treated with a short weekly chemotherapy regimen (doxorubicin, cyclophosphamide, bleomycin, vincristine, and prednisone) and involved field radiotherapy: result of a Gruppo Italiano Multiregionale per lo Studio dei Linfomi e Leucenie (GIMURELL) study.
Cabras MG; Mamusa AM; Vitolo U; Freilone R R; Dessalvi P; Orsucci L; Tonso A; Levis A; Liberati M; Lay G; Angelucci E
Leuk Lymphoma; 2009 Sep; 50(9):1475-81. PubMed ID: 19579074
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological features and prognostic factors in extranodal non-Hodgkin lymphomas. Danish LYFO Study Group.
d'Amore F; Christensen BE; Brincker H; Pedersen NT; Thorling K; Hastrup J; Pedersen M; Jensen MK; Johansen P; Andersen E
Eur J Cancer; 1991; 27(10):1201-8. PubMed ID: 1835586
[TBL] [Abstract][Full Text] [Related]
32. Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas.
Schlembach PJ; Wilder RB; Tucker SL; Ha CS; Rodriguez MA; Hess MA; Cabanillas FF; Cox JD
Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1107-10. PubMed ID: 11072169
[TBL] [Abstract][Full Text] [Related]
33. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.
Sonneveld P; de Ridder M; van der Lelie H; Nieuwenhuis K; Schouten H; Mulder A; van Reijswoud I; Hop W; Lowenberg B
J Clin Oncol; 1995 Oct; 13(10):2530-9. PubMed ID: 7595704
[TBL] [Abstract][Full Text] [Related]
34. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone.
Navarro JT; Ribera JM; Oriol A; Vaquero M; Romeu J; Batlle M; Flores A; Millá F; Feliu E
Br J Haematol; 2001 Mar; 112(4):909-15. PubMed ID: 11298585
[TBL] [Abstract][Full Text] [Related]
35. Angiogenic and coagulation-fibrinolysis factors in non Hodgkin's lymphoma.
Wróbel T; Poreba M; Mazur G; Poreba R; Pyszel A; Beck B; Steinmetz-Beck A; Andrzejak R; Kuliczkowski K
Neoplasma; 2006; 53(3):253-8. PubMed ID: 16652197
[TBL] [Abstract][Full Text] [Related]
36. Dose-intensified CHOP (double-CHOP) followed by consolidation with high-dose chemotherapy for high and high-intermediate risk aggressive non-Hodgkin's lymphomas.
Yamazaki T; Sawada U; Kura Y; Ito T; Kaneita Y; Yasukawa K; Horie T
Leuk Lymphoma; 2002 Nov; 43(11):2117-23. PubMed ID: 12533036
[TBL] [Abstract][Full Text] [Related]
37. [Clinical analysis of 282 patients with non-Hodgkin's lymphoma].
Chen SP; Wu DS; Zhao XL
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):237-9. PubMed ID: 14653077
[TBL] [Abstract][Full Text] [Related]
38. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations.
Tomita N; Kodama F; Sakai R; Koharasawa H; Hattori M; Taguchi J; Fujita H; Tanabe J; Fujisawa S; Fukawa H; Harano H; Kanamori H; Miyashita H; Matsuzaki M; Ogawa K; Motomura S; Maruta A; Ishigatsubo Y
Leuk Lymphoma; 2000 Jul; 38(3-4):335-43. PubMed ID: 10830740
[TBL] [Abstract][Full Text] [Related]
39. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
Vaccher E; Spina M; di Gennaro G; Talamini R; Nasti G; Schioppa O; Vultaggio G; Tirelli U
Cancer; 2001 Jan; 91(1):155-63. PubMed ID: 11148572
[TBL] [Abstract][Full Text] [Related]
40. High serum angiogenin at diagnosis predicts for failure on long-term treatment response and for poor overall survival in non-Hodgkin lymphoma.
Fang S; Repo H; Joensuu H; Orpana A; Salven P
Eur J Cancer; 2011 Jul; 47(11):1708-16. PubMed ID: 21439815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
